Both in vivo and in vitro experiments demonstrated that serum SHBG levels are reduced in NAFLD and that accumulation of hepatic fat rather than whole body fat is the determinant of decreased circulating SHBG expression [52]. The gene discussed is SHBG; the disease is metabolic dysfunction-associated steatotic liver disease.